Studies protein and gene patterns in breast cancer tumours
Examines tumour proteins and receptor genes in adults with primary or recurrent breast cancer.
Plain-language title generated from the registry record
Registry title: Breast Cancer Proteomics and Molecular Heterogeneity
Key facts
- Where
- Cork, Dublin, Limerick, and Waterford, IrelandSee the 6 sites
Where in Ireland
- Cork University HospitalCork, IrelandTaking people
- Beaumont HospitalDublin, IrelandTaking people
- St Vincent's University HospitalDublin, IrelandTaking people
- St. James's HospitalDublin, IrelandNo longer taking part
- University Hospital LimerickLimerick, IrelandNo longer taking part
- University Hospital WaterfordWaterford, IrelandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Trials Ireland
- Trial code
- NCT01840293
- Record updated
- 19 December 2025
- Original description
Primary objective:Read full original descriptionShow less
Breast Cancer Proteomics and Molecular Heterogeneity
Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
Inclusion: Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue; Or; -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue; Or; -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue; Patients receiving neoadjuvant treatment are also eligible (if applicable); Patients have to be ≥ 18 years of age; Patients must be able to give informed consent.